<DOC>
	<DOC>NCT02370979</DOC>
	<brief_summary>This is a multi-center prospective study. The primary objective of DRONE study is to investigate the change of the size of HIV-1 DNA reservoir in blood from baseline to week 48 (W48) in participants treated by DTG-based regimen. Secondary objectives include: DTG pharmacokinetic and analysis of biomarkers of immune activation from baseline to W48.</brief_summary>
	<brief_title>Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Na√Øve and Experienced Patients</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Male or female aged from de 18 to 80 years Patient starting a DTGregimen Patients agreeing to use methods of birthcontrol while on the study and during the 6 weeks after stopping DTG treatment Signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening Women who are pregnant or breastfeeding HBV or HCV coinfection Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted An active AIDSdefining condition at Screening Documented resistance to DTG Allergy or intolerance to the study drugs or their components or drugs of their class Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4 lipids) at Screening. Coadministration with Dofelitide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Dolutegravir</keyword>
	<keyword>Proviral HIV-1 DNA</keyword>
	<keyword>Reservoir</keyword>
</DOC>